SP-624
Phase 2- Indications
- Major depressive disorder
Company intelligence / Profile preview
Sirtsei Pharmaceuticals, Inc.
Morrisville, North Carolina, United Statesarrivobio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
SP-624 (forvisirvat) demonstrated statistically significant and clinically meaningful efficacy in female patients with Major Depressive Disorder in a Phase 2 study. The drug showed improvement on the MADRS total score compared to placebo at Week 4, as well as across multiple clinician- and patient-rated depression scales. The drug was well tolerated.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sirtsei Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sirtsei Pharmaceuticals, Inc..